Triple class refractory multiple myeloma
10 Nov 2021
Triple class refractory multiple myeloma
Managing immune-related adverse effects in Africa
Palliative care in Africa
Managing high-risk/MRD positive and standard-risk/MRD myeloma
Minimum residual disease techniques in myeloma
Rescue after daratumumab failure
Programme topics at AORTIC 2021 virtual
Pathogenesis of colon adenocarcinoma in Kerala, India
ESMO 2021: Latest in EGFR mutated advanced NSCLC
First-line nivolumab + ipilimumab + chemo in patients with advanced NSCLC and brain metastases: Results From CheckMate 9LA
Trastuzumab deruxtecan vs trastuzumab emtansine in patients with HER2+ metastatic breast cancer
ESMO 2021: PARPi data and their role in mono/combination therapies